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recently been stressed (Fitzgerald, ClGn. exp.
Immunol., 1971, 8, 421). Twenty-one
patients and the same number of age-
matched controls were studied. Lympho-
cyte transformation was induced at seven
concentrations of PHA and the response
measured by the incorporation of [14C]-
thymidine. Using the data obtained, dose
response curves were plotted for both the
cancer and control patients. A statistically
highly significant difference between the two
groups emerged at three different concentra-
tions. This was considered to reflect a
depression in " T " lymphocyte function but
it was not possible to say whether this was
due to a deficiency in the cells themselves or
due to a serum inhibitory factor.
INHIBITION OF CELL MEDIATED
CYTOTOXICITY AGAINST HUMAN
COLON CARCINOMATA BY PAPAIN-
SOLUBILIZED TUMOUR MEMBRANE
EXTRACTS. M. J. EMBLETON and M. R.
PRICE. Cancer Research Campaign Labora-
tories, University of Nottingham.
Studies were undertaken to determine
whether soluble tumour antigen preparations
can infiuence cytotoxicity against cultured
colon carcinoma cells by lymphocytes from
colon carcinoma patients.
Peripheral lymphocytes from 61% of
tumour bearing or post-operative patients
were cytotoxic for colon carcinoma cells
compared with normal control lymphocytes,
as assayed by their capacity to reduce the
survival of target cells in microtitration
plates. Papain-solubilized membrane ex-
tracts were prepared from pooled colon
carcinomata, normal colon and melanoma,
and their effect on cell mediated cytotoxicity
was measured by incubation with patients'
and control lymphocytes before addition of
the lymphocytes to target cells. Colon
carcinoma extracts inhibited cytotoxicity
but normal colon or melanoma extracts had
no effect. The inhibition of lymphocyte
reactivity by soluble antigen may have
important implications regarding the possible
modification of tumour-immune reactions
in vivo by circulating tumour antigen.
BCG IMMUNOTHERAPY OF RAT
SARCOMATA. R. W. BALDWIN and M. V.
PIMM. Cancer Research Campaign Labora-
tories, University of Nottingham.
Growth of immunogenic 3-methylchol-
anthrene induced rat sarcomata was suppres-
sed if tumour cells were transplanted sub-
cutaneously in admixture with as little as
10 ,ug of viable BCG. Animals rejecting
sarcoma cell-BCG inocula were subsequently
immune to challenge with the same tumour,
indicating the involvement of host responses
to tumour associated rejection antigens.
Furthermore, rejection of mixed inocula
suppressed growth of a simultaneous chal-
lenge of the same sarcoma at another site.
This specific active immunotherapy was
successful even if given after tumour
challenge.
Pulmonary growth ofintravenously trans-
ferred sarcoma cells was also controlled by
this form of active immunotherapy. More
effective control was obtained by intra-
venous administration of BCG alone, even if
delayed up to 7 days after challenge, perhaps
reflecting preferential pulmonary survival of
BCG and direct contact with tumour cells at
this site.
THE ROLE OF MACROPHAGES IN
CLASSIC MAREK'S DISEASE. J. C.
CAMPBELL. Cancer Research Campaign
Unit, Department of Veterinary Pathology,
Bush House, Milton Bridge, Midlothian.
Marek's disease is a contagious lympho-
proliferative condition of chickens caused by
a herpesvirus Type B and exhibits neural
and visceral forms. Cells involved are
mainly lymphocytes and plasmacytes.
Lesions may terminate as lymphomata.
Indirect and direct immunofluorescence
of cryostat sections and serosal spreads show
antigen mainly confined to histiocytes,
though vascular endothelium and neurilemma
are frequently positive and lymphoid foci
occasionally so. Fresh buffy coat prepara-
tions show positively staining monocytes
which metamorphose in culture to motile
macrophages. Lymphocytes adhere to
these, forming conspicuous immunofluores-
cent clusters. Intercellular bridging be-
tween macrophages leads to the formation of
immunofluorescent-positive polykaryocytes.
Lymphocytes containing macrophage-en-
dowed viral genome respond to the blasto-
genic effect of phytohaemagglutinin in vitro
and naked nucleoplasmic virions appear
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(Campbell and Woode, J. med. Microbiol.,
1970, 3, 463). Intracranial injection of
lymphocyte cultures containing transformed
cells has produced cerebral lymphomata in
chickens.
DIAGNOSTIC AND PROGNOSTIC
SIGNIFICANCE OF DELAYED HYPER-
SENSITIVITY SKIN TESTING IN
PATIENTS WITH MALIGNANT
NEOPLASIA. P. M. BOLTON, S. L.
JAMES, J. DAVIDSON and L. E. HUGHES.
University Department of Surgery, Welsh
National School of Medicine, Cardiff.
Impairment of delayed hypersensitivity
is a feature of advanced malignancy. Eilber
and Morton (Cancer, N.Y., 1970, 25, 362)
studied the response to D.N.C.B. in cancer
patients and concluded that an impaired
response indicated a poor prognosis.
We have investigated Mantoux and
D.N.C.B. responses in 112 patients with
solitary breast lumps and in 54 patients with
suspected gastric or colonic neoplasia. Re-
sults were assessed in relation to final
diagnosis (benign or malignant), tumour
staging and prognosis.
Patients with benign breast lumps were
nearly always D.N.C.B. positive, while
impaired responses occurred in 60% of
patients with breast cancer and haemato-
genous dissemination. Conversion from
negative to positive was associated with a
good response to treatment, whereas persis-
tent negativity implied a poor prognosis.
Patients with gastrointestinal malignancy
exhibited impairment of D.N.C.B. and
Mantoux tests compared with controls.
Positive tests indicated a better
prognosis.
Serial testing of delayed hypersensitivity
correlates with the course of the disease in
cancer patients.
GROWTH INHIBITORY EFFECT OF
PERITONEAL MACROPHAGES ON
HARDING PASSEY MELANOMA, ITS
IMPAIRMENT BY MACROPHAGE
LYSOSOME OVERLOADING. F. J.
LEJEUNE, E. BEAUMONT and Y. GARCIA.
Department of Surgery, Institut Ju1es-
Bordet, Brussels.
Repeated i.p. inoculations of irradiated
Harding-Passey melanoma cells (HPM) in-
duced an immune protection of mice against
living HPM graft. In vitro, spleen cells from
immune animals were found to produce a
strong growth inhibition of HPM. How-
ever, peritoneal macrophages taken 7 days
after immunization were less inhibitory than
controls. The spontaneous cytotoxicity of
control macrophages was recovered by
macrophages taken 31 days after immuniza-
tion. An electron microscopy study of the
macrophages showed lysosome overloading
with melanin on Day 7 and an important
clearing of lysosomes on Day 31.
Preliminary experiments showed that it
was possible to neutralize the inherent cyto-
toxicity of normal peritoneal macrophages
by feeding them with melanin in culture.
Explants and primary cultures of HPM
were found to contain a consistent amount of
macrophages filled with melanin. It is
suggested that malignant melanocytes can
neutralize macrophage cytotoxicity by over-
loading their lysosomes with melanin.
CHANGES IN GROWTH AND
ADHESION OF EHRLICH ASCITES
TUMOUR CELLS COATED WITH
TRYPSIN INHIBITOR (SOYBEAN).
P. WHUR, R. T. ROBSON and N. E. PAYNE.
Cell Biology Unit, Marie Curie Memorial
Foundation, Research Department, Oxted,
Surrey.
We report an attempt to inhibit tumour
growth using a non-agglutinating plant
protein. Mice injected i.p. with tumour cells
and subsequently with trypsin inhibitor
showed a 92% reduction of recoverable cells
compared with untreated controls after
8 days of tumour growth. No differences
were detected in rates of DNA synthesis in
vitro, but experiments in vivo indicated that
treated cells grew slightly faster. Trypsin
inhibitor, which binds to the cell surface, was
non-toxic to the treated cells. Scanning EM
micrographs showed that treated cells, unlike
untreated cells, adhered to internal abdomi-
nal surfaces, and treated cells also showed
increased agglutinability with concanavalin
A in vitro. These findings are generally
compatible with the possible existence of an
intrinsic protease, which becomes inhibited in
treated cells.